NCCN Guidelines Update: Impact of Ipilimumab and Nivolumab as Preferred Regimen for ccRCC

David Braun, MD, PhD, of the Yale School of Medicine, shares insights on the recent updates to the NCCN guidelines, focusing on the inclusion of ipilimumab and nivolumab as a preferred regimen for favorable-risk clear cell renal cell carcinoma (ccRCC). Dr. Braun provides an in-depth analysis of the long-term data from the CheckMate-214 trial, highlighting how this shift in treatment protocols could influence clinical practices. He also explores the broader implications of these changes, including advancements in diagnostic tools, personalized treatment planning, and the evolving role of combination immunotherapy in the management of ccRCC.
For more video insights, visit guoncologynow....